blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2408796

EP2408796 - Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III [Right-click to bookmark this link]
Former [2012/04]TARGETING APOLIPOPROTEIN B FOR THE REDUCTION OF APOLIPOPROTEIN C-III
[2018/47]
StatusNo opposition filed within time limit
Status updated on  26.02.2021
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  20.03.2020
FormerGrant of patent is intended
Status updated on  24.10.2019
FormerExamination is in progress
Status updated on  09.08.2019
FormerGrant of patent is intended
Status updated on  17.12.2018
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
For all designated states
President and Fellows of Harvard College
Holyoke Center, 727
1350 Massachusetts Ave.
Cambridge, MA 02138 / US
[2019/02]
Former [2016/07]For all designated states
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
For all designated states
The President and Fellows of Harvard College
Holyoke Center, Suite 727
1350 Massachusetts Avenue
Cambridge, MA 02138 / US
Former [2012/04]For all designated states
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
For all designated states
The President and Fellows of Harvard College
Holyoke Center, Suite 727 1350 Massachusetts Avenue
Cambridge, MA 02138 / US
Inventor(s)01 / SACKS, Frank, M.
129 Leonard Street
Belmont MA 02478 / US
02 / TRIBBLE, Diane
5154 Whitman Way 313
Carlsbad CA 92008 / US
 [2012/04]
Representative(s)Chapman, Desmond Mark, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2020/17]
Former [2012/04]Chapman, Desmond Mark, et al
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Application number, filing date10754009.816.03.2010
[2020/17]
WO2010US27541
Priority number, dateUS20090160671P16.03.2009         Original published format: US 160671 P
[2012/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010107838
Date:23.09.2010
Language:EN
[2010/38]
Type: A1 Application with search report 
No.:EP2408796
Date:25.01.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 23.09.2010 takes the place of the publication of the European patent application.
[2012/04]
Type: B1 Patent specification 
No.:EP2408796
Date:22.04.2020
Language:EN
[2020/17]
Search report(s)International search report - published on:US23.09.2010
(Supplementary) European search report - dispatched on:EP19.12.2012
ClassificationIPC:A61K31/7088, A61P9/00, A61P3/08, A61P3/06
[2018/46]
CPC:
A61K31/7088 (EP,US); A61P3/06 (EP); A61P3/08 (EP);
A61P3/10 (EP); A61P9/00 (EP)
Former IPC [2013/03]C07H21/04, A61K31/7088, A61P9/00
Former IPC [2012/04]C07H21/04, A61K31/7088
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/04]
Extension statesALNot yet paid
BANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:Targeting Apolipoprotein B für die Reduktion von Apolipoprotein C-III[2018/46]
English:Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III[2018/47]
French:Ciblage de l'Apolipoprotéine B pour la réduction de l'apolipoprotéine C-III[2018/47]
Former [2012/04]APOLIPOPROTEIN-B-TARGETIN ZUR REDUKTION VON APOLIPOPROTEIN C-III
Former [2012/04]TARGETING APOLIPOPROTEIN B FOR THE REDUCTION OF APOLIPOPROTEIN C-III
Former [2012/04]CIBLAGE DE L'APOLIPOPROTÉINE B POUR LA RÉDUCTION DE L'APOLIPOPROTÉINE C-III
Entry into regional phase10.10.2011National basic fee paid 
10.10.2011Search fee paid 
10.10.2011Designation fee(s) paid 
10.10.2011Examination fee paid 
Examination procedure10.10.2011Examination requested  [2012/04]
17.07.2013Amendment by applicant (claims and/or description)
31.07.2014Despatch of a communication from the examining division (Time limit: M06)
21.05.2015Reply to a communication from the examining division
10.10.2018Cancellation of oral proceeding that was planned for 18.10.2018
18.10.2018Date of oral proceedings (cancelled)
18.12.2018Communication of intention to grant the patent
03.06.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
07.08.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
25.10.2019Communication of intention to grant the patent
25.02.2020Fee for grant paid
25.02.2020Fee for publishing/printing paid
25.02.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  31.07.2014
Opposition(s)25.01.2021No opposition filed within time limit [2021/13]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
07.08.2019Request for further processing filed
07.08.2019Full payment received (date of receipt of payment)
Request granted
19.08.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
21.05.2015Request for further processing filed
21.05.2015Full payment received (date of receipt of payment)
Request granted
08.06.2015Decision despatched
Fees paidRenewal fee
07.03.2012Renewal fee patent year 03
30.01.2013Renewal fee patent year 04
30.01.2014Renewal fee patent year 05
06.03.2015Renewal fee patent year 06
10.03.2016Renewal fee patent year 07
10.03.2017Renewal fee patent year 08
13.03.2018Renewal fee patent year 09
13.03.2019Renewal fee patent year 10
12.03.2020Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.03.2010
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
MK22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
TR22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
[2024/29]
Former [2024/22]HU16.03.2010
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
MK22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2023/27]HU16.03.2010
AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2023/24]AT22.04.2020
CY22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/45]AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
MC22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/24]AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
SE22.04.2020
SI22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/10]AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
PL22.04.2020
RO22.04.2020
SE22.04.2020
SK22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/09]AT22.04.2020
CZ22.04.2020
DK22.04.2020
EE22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
IT22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
RO22.04.2020
SE22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/08]DK22.04.2020
ES22.04.2020
FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
RO22.04.2020
SE22.04.2020
SM22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2021/01]FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
SE22.04.2020
BG22.07.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2020/50]FI22.04.2020
HR22.04.2020
LT22.04.2020
LV22.04.2020
NL22.04.2020
SE22.04.2020
NO22.07.2020
GR23.07.2020
IS22.08.2020
PT24.08.2020
Former [2020/48]FI22.04.2020
LT22.04.2020
NL22.04.2020
SE22.04.2020
NO22.07.2020
IS22.08.2020
PT24.08.2020
Former [2020/47]LT22.04.2020
NO22.07.2020
IS22.08.2020
Former [2020/46]IS22.08.2020
Documents cited:Search[XI]US2006035858  (GEARY RICHARD S [US], et al) [X] 1-11 * claims 1-35 * * page 14, paragraph 270 * [I] 12-15;
 [I]  - CHAN DICK C ET AL, "Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, (20020801), vol. 51, no. 8, doi:10.1053/META.2002.33339, ISSN 0026-0495, pages 1041 - 1046, XP002508090 [I] 12-15 * page 1054, paragraph 4 *

DOI:   http://dx.doi.org/10.1053/meta.2002.33339
 [I]  - MERKI E (MERKI ESTHER)1 ET AL, "A second generation antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on apolipoprotein B-100 particles in lipoprotein(a)-transgenic mice", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, (20080311), vol. 51, no. 10, Suppl.1, ISSN 0735-1097, page A294, XP009165215 [I] 12-15 * the whole document *
 [I]  - anonymous, "ISIS-301012", (2007), PROUS, URL: http://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml_show_ficha_ref?p_ref_id=1132978, (20121129), XP002688241 [I] 12-15 * the whole document *
International search[Y]US2006035858  (GEARY RICHARD S [US], et al);
 [Y]US2008146788  (BHAT BALKRISHEN [US], et al);
 [Y]  - CHAN ET AL., APOLIPOPROTEIN B-100 KINETICS IN VISCERAL OBESITY: ASSOCIATIONS WITH PLASMA APOLIPOPROTEIN C-III CONCENTRATION METABOLISM, (200208), vol. 51, no. 8, pages 1041 - 1046, XP002508090

DOI:   http://dx.doi.org/10.1053/meta.2002.33339
by applicantWO9914226
 WO03004602
 WO2004044181
 US2005130923
 US2006035858
 WO2007134181
 WO2008101157
    - KNOPP, New Engl. J. Medicine,, (19990000), vol. 341, pages 498 - 511
    - DAVIS; HUI, Arterioscler. Thromb. Vase. Biol., (20010000), vol. 21, pages 887 - 898
    - BONOW, Circulation, (20020000), vol. 106, pages 3140 - 3141
    - DAVIDSON; SHELNESS, Annu. Rev. Nutr., (20000000), vol. 20, pages 169 - 193
    - CAMPOS et al., "Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia", J. Lipid Res., (20010000), vol. 42, pages 1239 - 1249
    - Arch. Int. Med., (19880000), vol. 148, pages 36 - 39
    - LEE et al., Arteriosclerosis, Thrombosis, and Vascular Biology, (20030000), vol. 23, pages 853 - 858
    - YAMAMOTO et al., Diabetes, (20030000), vol. 52, pages 1155 - 1162
    - PITTNER et al., Int. J. Obes. Relat. Metab. Disord., (20040000), vol. 28, pages 963 - 71
    - HEYMSFIELD S B, Archives of Internal Medicine, (20000000), vol. 160, pages 1321 - 1326
    - "GenBank", Database accession no. NM 000384.1
    - "GenBank", Database accession no. NM_000384.1
    - "GenBank", Database accession no. NM -000384.2
    - "GenBank", Database accession no. M19734.1
    - "GenBank", Database accession no. Ml 8471.1
    - "GenBank", Database accession no. Ml 7779.1
    - "GenBank", Database accession no. X04714.1
    - "GenBank", Database accession no. M14162.1
    - "GenBank", Database accession no. NT 022227.9
    - "GenBank", Database accession no. AI249040.1
    - WOOLF et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 7305 - 7309
    - GAUTSCHI et al., J. Natl. Cancer Inst., (20010300), vol. 93, pages 463 - 471
    - MAHER; DOLNICK, Nuc. Acid. Res., (19880000), vol. 16, pages 3341 - 3358
    - Sanghvi, Y.S., Crooke, S.T. and Lebleu, B.,, Antisense Research and Applications, CRC Press, (19930000), pages 276 - 278
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, page 403 410
    - ZHANG; MADDEN, Genome Res., (19970000), vol. 7, page 649 656
    - SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482 489
    - JONES, L.J. et al., Analytical Biochemistry, (19980000), vol. 265, pages 368 - 374
    - "GenBank", Database accession no. M 14162.1
    - CAMPOS et al., "Distinct patterns of lipoproteins with ApoB defined by presence of ApoE or ApoC-III in hypercholesterolemia and hypertriglyceridemia", J. Lipid Res., (20010000), vol. 42, pages 1239 - 1249
    - KHOO et al., "Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content", J. Lipid Res., (19990000), vol. 40, pages 202 - 212, XP008130379
    - "The isolation and quantitative analysis of serum lipoproteins", LINDGREN, F. T.; L. C. JENSEN; F. T. HATCH., Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism, John Wiley-Interscience, (19720000), pages 181 - 274
    - "GenBank", Database accession no. L04150.1
 US20030712795
 US20040553722
 US20050123656
 US20050573537
 US20050200710
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.